Multi-center, randomized, double-blind phase II study of sorafenib or placebo with best supportive care after failure of deocetaxol in metastatic hormone-refractory prostate cancer.
Phase of Trial: Phase II
Latest Information Update: 12 Oct 2015
At a glance
- Drugs Sorafenib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 10 Oct 2015 Status changed from recruiting to completed as per European Clinical Trials Database record.
- 31 May 2011 New trial record